Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | SCD | O00767 | 3/20 | 0.38 |
| ▸ | AURKA | O14965 | 6/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.37 |
| ▸ | INCENP | Q9NQS7 | 5/20 | 0.37 |
| ▸ | TYRO3 | Q06418 | 3/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | MPL | P40238 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2298452 | 0.85 | SCD (0.49) | SCDCYP3A4CYP2D6 | |
| SCHEMBL14957434 | 0.81 | SLC6A2 (0.66) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3117365 | 0.80 | SLC6A2 (0.64) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL28468855 | 0.73 | IDO1 (0.41) | MPL | |
| SCHEMBL2300625 | 0.72 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2301366 | 0.71 | PDE3B (0.40) | SLC6A2SLC6A4SLC6A3SCN9A | |
| SCHEMBL3512541 | 0.71 | RBP4 (0.49) | SCDCYP2D6 | |
| SCHEMBL2297472 | 0.70 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3SCN9A | |
| SCHEMBL4511619 | 0.70 | AR (0.44) | CYP3A4CYP2D6 | |
| SCHEMBL3118290 | 0.69 | SCD (0.53) | SCDCYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9334269-B2 | Carboxamides as inhibitors of voltage-gated sodium channels | AMGEN INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20130131035-A1 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2536689-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | Amgen Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011103196-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | AMGEN INC. (US) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131035-A1 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | CACNA1B, SCN1A, CACNA1I | SLC6A2 475/4885SLC6A4 502/4885SLC6A3 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.